SG160185A1 - Pharmaceutical compositions comprising fluvastatin - Google Patents

Pharmaceutical compositions comprising fluvastatin

Info

Publication number: SG160185A1
Authority: SG; Singapore
Prior art keywords: fluvastatin; pharmaceutical compositions; pharmaceutical; gels; preventing
Prior art date: 2000-04-13

Application number

SG200500024-5A

Other languages

English (en)

Inventor

Oskar Michael Kalb

Stephen John Valazza

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-13

Filing date

2001-04-11

Publication date

2010-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24192117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG160185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-11 Application filed by Novartis Ag filed Critical Novartis Ag

2010-04-29 Publication of SG160185A1 publication Critical patent/SG160185A1/en

Links

229960003765 fluvastatin Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 title 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000000499 gel Substances 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)

SG200500024-5A 2000-04-13 2001-04-11 Pharmaceutical compositions comprising fluvastatin SG160185A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/549,222 US6242003B1 (en)	2000-04-13	2000-04-13	Organic compounds

Publications (1)

Publication Number	Publication Date
SG160185A1 true SG160185A1 (en)	2010-04-29

Family

ID=24192117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200500024-5A SG160185A1 (en)	2000-04-13	2001-04-11	Pharmaceutical compositions comprising fluvastatin

Country Status (20)

Country	Link
US (3)	US6242003B1 (pl)
EP (2)	EP1272166A2 (pl)
JP (2)	JP2003530422A (pl)
KR (1)	KR100510856B1 (pl)
CN (2)	CN100457102C (pl)
AU (2)	AU6219601A (pl)
BR (1)	BR0109943A (pl)
CA (1)	CA2403591A1 (pl)
CZ (1)	CZ20023379A3 (pl)
HU (1)	HUP0300541A3 (pl)
IL (2)	IL152077A0 (pl)
MX (1)	MXPA02010136A (pl)
NO (1)	NO20024891L (pl)
NZ (1)	NZ521441A (pl)
PL (1)	PL201268B1 (pl)
RU (1)	RU2297223C2 (pl)
SG (1)	SG160185A1 (pl)
SK (1)	SK14622002A3 (pl)
WO (1)	WO2001078680A2 (pl)
ZA (1)	ZA200208163B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8236352B2 (en)	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US8293277B2 (en)	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
US20020169145A1 (en) *	1998-10-14	2002-11-14	Rajen Shah	Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US7521068B2 (en)	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
CA2389616A1 (en) *	1999-11-03	2001-05-10	Howard J. Smith & Associates Pty Ltd.	Liver selective therapy
US6242003B1 (en) *	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
US7198795B2 (en)	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20060127474A1 (en) *	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
DK1471887T3 (da)	2002-02-04	2010-06-07	Elan Pharma Int Ltd	Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
CA2475722A1 (en) *	2002-02-14	2003-08-21	Romi Barat Singh	Formulations of atorvastatin stabilized with alkali metal additions
WO2003103640A1 (en) *	2002-06-10	2003-12-18	Elan Pharma International, Ltd	Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
ES2315510T3 (es) *	2002-06-13	2009-04-01	Novartis Ag	Sales de calcio de estatinas derivadas del indol.
GB0217306D0 (en) *	2002-07-25	2002-09-04	Novartis Ag	Compositions comprising organic compounds
AU2004222436A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
PT1603553E (pt) *	2003-03-17	2012-02-03	Japan Tobacco Inc	Composições farmacêuticas de inibidores de cetp
US20040185093A1 (en) *	2003-03-18	2004-09-23	Szymczak Christopher E.	Compositions containing sucralose
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7790197B2 (en) *	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
CN100502832C (zh) *	2003-10-27	2009-06-24	荷兰联合利华有限公司	护发组合物
US20050220875A1 (en) *	2004-03-31	2005-10-06	Agency For Science, Technology And Research	Sustained-release tablet formulation
US20060062811A1 (en) *	2004-09-21	2006-03-23	Szymczak Christopher E	Medicinal cooling emulsions
CA2589537A1 (en) *	2004-12-02	2006-06-08	Stephen Craig Dyar	Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
CA2626309A1 (en) *	2005-10-31	2007-05-10	Kowa Co., Ltd.	Pharmaceutical preparation containing pitavastatin with excellent photostability
BRPI0708191A2 (pt) *	2006-02-24	2012-05-29	Teva Pharma	" composições farmacêuticas de fluvastatina sódica "
EP1911441A3 (en) *	2006-10-11	2008-08-06	Lupin Limited	Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
US20110052688A1 (en) *	2006-11-21	2011-03-03	San-Laung Chow	Solid dispersion composition
US20080132560A1 (en) *	2006-11-21	2008-06-05	San-Laung Chow	Solid dispersion composition
KR101408454B1 (ko) *	2006-12-01	2014-06-17	닛토덴코 가부시키가이샤	도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
JP5237112B2 (ja) *	2006-12-01	2013-07-17	日東電工株式会社	経皮吸収製剤
FR2918567B1 (fr) *	2007-07-11	2012-08-03	Pf Medicament	Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
RU2483729C2 (ru) *	2008-05-30	2013-06-10	Нитто Денко Корпорейшн	Чрескожно абсорбируемый препарат
RU2481826C2 (ru) *	2008-05-30	2013-05-20	Нитто Денко Корпорейшн	Содержащий донепезил адгезивный препарат и упаковка для него
CN102805739B (zh) *	2012-04-10	2013-08-14	宋芸	氟伐他汀钠缓释包衣滴丸及其制备方法
CN106344535B (zh) *	2016-08-29	2019-09-20	济南康和医药科技有限公司	一种氟伐他汀钠微孔渗透泵控释片及其制备方法
US10600502B2 (en)	2016-12-20	2020-03-24	Astrazeneca Uk Ltd.	Systems and methods for dispensing a statin medication over the counter
US20220008519A1 (en)	2020-07-09	2022-01-13	Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS)	Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT401872B (de) *	1991-12-12	1996-12-27	Sandoz Ag	Stabilisiertes pharmazeutisches mittel, enthaltend fluvastatin-natrium als wirkstoff
WO1998015264A1 (en) *	1996-10-08	1998-04-16	Astra Aktiebolag	PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870790A (en)	1970-01-22	1975-03-11	Forest Laboratories	Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en)	1970-03-23	1974-12-03	Shinetsu Chemical Co	Excipient and shaped medicaments prepared therewith
US3865935A (en)	1972-08-10	1975-02-11	Abbott Lab	Tableting of erythromycin base
US3952096A (en)	1973-06-15	1976-04-20	Bristol-Myers Company	Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent
US3891755A (en)	1973-07-11	1975-06-24	Abbott Lab	Dosage formulation for erythromycin cetyl sulfate
US4226849A (en)	1979-06-14	1980-10-07	Forest Laboratories Inc.	Sustained release therapeutic compositions
US4357469A (en)	1979-06-14	1982-11-02	Forest Laboratories, Inc.	Carrier base material for prolonged release therapeutic compositions
US4259314A (en)	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals
US4342767A (en)	1980-01-23	1982-08-03	Merck & Co., Inc.	Hypocholesteremic fermentation products
US4369172A (en)	1981-12-18	1983-01-18	Forest Laboratories Inc.	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en)	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en)	1982-06-24	1985-12-03	Key Pharmaceuticals, Inc.	Sustained release propranolol tablet
WO1984002131A1 (fr)	1982-11-22	1984-06-07	Sandoz Ag	Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
US4686237A (en)	1984-07-24	1987-08-11	Sandoz Pharmaceuticals Corp.	Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4744987A (en)	1985-03-08	1988-05-17	Fmc Corporation	Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
WO1987000044A1 (en)	1985-07-02	1987-01-15	The Upjohn Company	Therapeutic formulations with bimodal release characteristics
DE3524572A1 (de)	1985-07-10	1987-01-15	Thomae Gmbh Dr K	Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4734285A (en) *	1985-10-28	1988-03-29	The Dow Chemical Company	Sustained release compositions
US4755386A (en)	1986-01-22	1988-07-05	Schering Corporation	Buccal formulation
CA1327010C (en)	1986-02-13	1994-02-15	Tadashi Makino	Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPH0776172B2 (ja)	1986-04-16	1995-08-16	藤沢薬品工業株式会社	マトリツクス錠
GB2189699A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
GB2189698A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
GB8624213D0 (en)	1986-10-09	1986-11-12	Sandoz Canada Inc	Sustained release pharmaceutical compositions
US4786503A (en)	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
US4915954A (en)	1987-09-03	1990-04-10	Alza Corporation	Dosage form for delivering a drug at two different rates
US4929605A (en)	1987-10-07	1990-05-29	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol derivatives
US5030447A (en)	1988-03-31	1991-07-09	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions having good stability
US5376383A (en)	1988-11-21	1994-12-27	Merck & Co., Inc.	Method for enhancing the lowering of plasma-cholesterol levels
US4997658A (en)	1988-11-21	1991-03-05	Merck & Co., Inc.	Method for enhancing the lowering of plasma cholesterol levels
CA2007181C (en)	1989-01-06	1998-11-24	Angelo Mario Morella	Sustained release pharmaceutical composition
US5004651A (en)	1989-01-24	1991-04-02	Abbott Laboratories	Stabilizing system for solid dosage forms
US5126145A (en)	1989-04-13	1992-06-30	Upsher Smith Laboratories Inc	Controlled release tablet containing water soluble medicament
CA2016467A1 (en)	1989-06-05	1990-12-05	Martin Eisman	Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US5021053A (en)	1989-07-14	1991-06-04	Alza Corporation	Oral osmotic device with hydrogel driving member
US5009895A (en)	1990-02-02	1991-04-23	Merck & Co., Inc.	Sustained release with high and low viscosity HPMC
CA2045428A1 (en)	1990-06-26	1991-12-27	Alfred W. Alberts	Method for enhancing the lowering of plasma cholesterol levels
US5147654A (en)	1990-07-23	1992-09-15	Alza Corporation	Oral osmotic device for delivering nicotine
US5284662A (en)	1990-10-01	1994-02-08	Ciba-Geigy Corp.	Oral osmotic system for slightly soluble active agents
ATE113202T1 (de)	1990-11-29	1994-11-15	Wei Ming Pharmaceutical Mfg Co	Hilfsträger für direkte verpressung.
HU217629B (hu) *	1991-12-12	2000-03-28	Novartis Ag.	Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5543154A (en)	1991-12-27	1996-08-06	Merck & Co., Inc.	Controlled release nifedipine delivery device
ATE173159T1 (de)	1992-03-25	1998-11-15	Depomed Systems Inc	Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5472714A (en) *	1993-09-08	1995-12-05	Ciba-Geigy Corporation	Double-layered oxcarbazepine tablets
US5393765A (en)	1993-12-13	1995-02-28	Hoffmann-La Roche Inc.	Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6369103B1 (en) *	1994-01-18	2002-04-09	Bristol-Myers Squibb Company	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5419917A (en)	1994-02-14	1995-05-30	Andrx Pharmaceuticals, Inc.	Controlled release hydrogel formulation
US5582838A (en)	1994-12-22	1996-12-10	Merck & Co., Inc.	Controlled release drug suspension delivery device
US5624677A (en)	1995-06-13	1997-04-29	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
DE69625046T2 (de)	1995-12-22	2003-04-10	Kowa Co., Ltd.	Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
WO1997047285A1 (en)	1996-06-10	1997-12-18	Depomed, Inc.	Gastric-retentive oral controlled drug delivery system with enhanced retention properties
WO1997049681A1 (en)	1996-06-24	1997-12-31	Astra Aktiebolag (Publ)	Polymorphic compounds
US5972389A (en)	1996-09-19	1999-10-26	Depomed, Inc.	Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9603668D0 (sv)	1996-10-08	1996-10-08	Astra Ab	Pharmaceutical compositions
US5837379A (en) *	1997-01-31	1998-11-17	Andrx Pharmaceuticals, Inc.	Once daily pharmaceutical tablet having a unitary core
GB9703388D0 (en) *	1997-02-18	1997-04-09	Sandoz Yakuhin K K Tokyo Sykk	Organic compounds
BE1011045A3 (fr)	1997-03-14	1999-04-06	Ucb Sa	Compositions pharmaceutiques pour la liberation controlee de substances actives.
SI9700186B (sl)	1997-07-14	2006-10-31	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.	Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
CO5140079A1 (es) *	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
CA2405793A1 (en) *	2000-04-12	2001-10-18	Novartis Ag	Combination of organic compounds
US6242003B1 (en) *	2000-04-13	2001-06-05	Novartis Ag	Organic compounds

2000
- 2000-04-13 US US09/549,222 patent/US6242003B1/en not_active Expired - Lifetime
2001
- 2001-04-11 WO PCT/EP2001/004204 patent/WO2001078680A2/en not_active Ceased
- 2001-04-11 CN CNB2005100806269A patent/CN100457102C/zh not_active Expired - Fee Related
- 2001-04-11 IL IL15207701A patent/IL152077A0/xx active IP Right Grant
- 2001-04-11 JP JP2001575982A patent/JP2003530422A/ja not_active Withdrawn
- 2001-04-11 AU AU6219601A patent/AU6219601A/xx active Pending
- 2001-04-11 BR BR0109943-4A patent/BR0109943A/pt not_active Application Discontinuation
- 2001-04-11 KR KR10-2002-7012592A patent/KR100510856B1/ko not_active Expired - Fee Related
- 2001-04-11 SK SK1462-2002A patent/SK14622002A3/sk not_active Application Discontinuation
- 2001-04-11 MX MXPA02010136A patent/MXPA02010136A/es active IP Right Grant
- 2001-04-11 SG SG200500024-5A patent/SG160185A1/en unknown
- 2001-04-11 HU HU0300541A patent/HUP0300541A3/hu unknown
- 2001-04-11 CZ CZ20023379A patent/CZ20023379A3/cs unknown
- 2001-04-11 EP EP01936232A patent/EP1272166A2/en not_active Ceased
- 2001-04-11 CA CA002403591A patent/CA2403591A1/en not_active Abandoned
- 2001-04-11 CN CNB018079148A patent/CN1241545C/zh not_active Expired - Fee Related
- 2001-04-11 US US10/257,614 patent/US20030171419A1/en not_active Abandoned
- 2001-04-11 NZ NZ521441A patent/NZ521441A/en unknown
- 2001-04-11 AU AU2001262196A patent/AU2001262196B8/en not_active Ceased
- 2001-04-11 RU RU2002129570/15A patent/RU2297223C2/ru not_active IP Right Cessation
- 2001-04-11 EP EP08170891A patent/EP2042163A1/en not_active Withdrawn
- 2001-04-11 PL PL356904A patent/PL201268B1/pl not_active IP Right Cessation
- 2001-05-17 US US09/859,861 patent/US6432447B2/en not_active Expired - Lifetime
2002
- 2002-10-02 IL IL152077A patent/IL152077A/en not_active IP Right Cessation
- 2002-10-10 NO NO20024891A patent/NO20024891L/no not_active Application Discontinuation
- 2002-10-10 ZA ZA200208163A patent/ZA200208163B/xx unknown
2007
- 2007-02-22 JP JP2007042395A patent/JP2007131647A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT401872B (de) *	1991-12-12	1996-12-27	Sandoz Ag	Stabilisiertes pharmazeutisches mittel, enthaltend fluvastatin-natrium als wirkstoff
WO1998015264A1 (en) *	1996-10-08	1998-04-16	Astra Aktiebolag	PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANDBOOK OF PHARMACEUTICAL EXCIPIENTS *

Also Published As

Publication number	Publication date
MXPA02010136A (es)	2003-03-10
NO20024891D0 (no)	2002-10-10
US20030171419A1 (en)	2003-09-11
CN1241545C (zh)	2006-02-15
WO2001078680A2 (en)	2001-10-25
IL152077A (en)	2009-02-11
BR0109943A (pt)	2003-05-27
CA2403591A1 (en)	2001-10-25
JP2007131647A (ja)	2007-05-31
CN1720912A (zh)	2006-01-18
EP1272166A2 (en)	2003-01-08
AU2001262196B2 (en)	2005-08-11
US20010043950A1 (en)	2001-11-22
NO20024891L (no)	2002-12-05
RU2002129570A (ru)	2004-03-27
AU2001262196B8 (en)	2005-12-01
HUP0300541A2 (hu)	2003-07-28
EP2042163A1 (en)	2009-04-01
WO2001078680A3 (en)	2002-04-11
PL356904A1 (pl)	2004-07-12
ZA200208163B (en)	2003-08-26
HUP0300541A3 (en)	2009-04-28
US6242003B1 (en)	2001-06-05
KR100510856B1 (ko)	2005-08-31
CN1422151A (zh)	2003-06-04
KR20030019332A (ko)	2003-03-06
NZ521441A (en)	2004-08-27
CZ20023379A3 (cs)	2003-01-15
IL152077A0 (en)	2003-05-29
JP2003530422A (ja)	2003-10-14
AU6219601A (en)	2001-10-30
RU2297223C2 (ru)	2007-04-20
US6432447B2 (en)	2002-08-13
SK14622002A3 (sk)	2003-04-01
PL201268B1 (pl)	2009-03-31
CN100457102C (zh)	2009-02-04

Publication	Publication Date	Title
IL150225A0 (en)	2002-12-01	Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
ZA200208163B (en)	2003-08-26	Pharmaceutical compositions comprising fluvastatin.
NO2013004I1 (no)	2013-03-18	axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
MXPA01010676A (es)	2003-08-20	Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
IL151372A0 (en)	2003-04-10	Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same
IS5665A (is)	2000-10-13	Lyfjafræðileg þrýstiúða samsetning
ZA200004413B (en)	2001-05-22	Gelling ophthalmic compositions containing xanthan gum.
HUP0400644A3 (en)	2009-06-29	Pharmaceutical compositions containing aspirin
ZA200203486B (en)	2003-08-04	Novel pharmaceutical compositions.
GB0020691D0 (en)	2000-10-11	Pharmaceutical combination
ZA200000857B (en)	2001-05-31	Pharmaceutical composition.
MXPA03000624A (es)	2003-09-05	Composiciones y peliculas para la elaboracion de capsulas.
GB9904163D0 (en)	1999-04-14	Pharmaceutical compositions
AU2002214532A1 (en)	2002-04-15	Tender for production platforms
IL148725A0 (en)	2002-09-12	Aqueous pharmaceutical compositions containing circlesonide
GB9911017D0 (en)	1999-07-14	Pharmaceutical compositions
IL156372A0 (en)	2004-01-04	Carbazole derivatives and pharmaceutical compositions containing the same
AP2001002369A0 (en)	2001-12-31	Pharmaceutical complex.
GB9904911D0 (en)	1999-04-28	Pharmaceutical compositions
HUP0202594A3 (en)	2003-10-28	Streptogramin derivatives, production thereof and pharmaceutical compositions containing the same
GB0012293D0 (en)	2000-07-12	Pharmaceutical combination
ZA200002318B (en)	2000-11-16	Aqueous pharmaceutical composition.
AU4210001A (en)	2001-10-08	Pharmaceutical gel composition
HUP0401446A3 (en)	2006-11-28	Heterocondensated indole and heteroindole derivatives, the production and use thereof and pharmaceutical compositions containing them
HK1053420A (en)	2003-10-24	Pharmaceutical compositions comprising fluvastatin